Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Ist Teil von
The New England journal of medicine, 2015-07, Vol.373 (1), p.11-22
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2015
Quelle
MEDLINE
Beschreibungen/Notizen
This trial compared once-daily liraglutide, a glucagon-like peptide-1 analogue, with placebo in overweight or obese patients. Liraglutide was associated with clinically meaningful weight loss, a decrease in glycemia and risk factors, and improvement in quality of life.
The increase in the rate of obesity, a chronic disease with serious health consequences, largely explains the recent tripling in the prevalence of type 2 diabetes.
1
,
2
Weight loss of 5 to 10% has been shown to reduce complications related to obesity and improve quality of life
3
–
7
; however, weight loss is difficult to maintain with lifestyle intervention alone.
8
Liraglutide, a glucagon-like peptide-1 analogue with 97% homology to human glucagon-like peptide-1, is approved for the treatment of type 2 diabetes at doses up to 1.8 mg once daily.
9
Weight loss with liraglutide is dose-dependent up to 3.0 mg once . . .